Department of Internal Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri; The Genome Institute, Washington University, St. Louis, Missouri.
Cancer. 2014 Apr 15;120(8):1134-44. doi: 10.1002/cncr.28552. Epub 2014 Jan 28.
Since its use in the initial characterization of an acute myeloid leukemia (AML) genome, next-generation sequencing (NGS) has continued to molecularly refine the disease. Here, the authors review the spectrum of NGS applications that have subsequently delineated the prognostic significance and biologic consequences of these mutations. Furthermore, the role of this technology in providing a high-resolution glimpse of AML clonal heterogeneity, which may inform future choice of targeted therapy, is discussed. Although obstacles remain in applying these techniques clinically, they have already had an impact on patient care.
自其在急性髓细胞白血病（AML）基因组的初步特征描述中使用以来，下一代测序（NGS）不断对该疾病进行分子细化。在这里，作者回顾了随后描绘这些突变的预后意义和生物学后果的 NGS 应用范围。此外，还讨论了该技术在提供 AML 克隆异质性的高分辨率观察方面的作用，这可能为未来的靶向治疗选择提供信息。尽管在临床应用这些技术方面仍然存在障碍，但它们已经对患者护理产生了影响。
